Launch week offerEnds in00h00m00s

annual Promonthly Pro

Patrick R Lawler

Has grant

Associate Professor

McGill University

Canada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Canada

Recent Grants

Grant: Open

Enabling Bayesian Clinical Trials: Improving the use of Bayesian methods in randomised clinical trials of efficacy and effectiveness (Co-Investigator)

Open Date: 2026-01-01

Close Date: 2031-01-01

Grant: Close

Precision medicine Adaptive Network platform Trial in Hypoxemic acutE respiratory failuRe (PANTHER). (Co-Investigator)

Open Date: 2025-01-01

Close Date: 2026-01-01

Grant: Open

Transforming Sepsis Care: Robust prediction and decision making leveraging the Social Determinants of Health (Co-Investigator)

Open Date: 2025-01-01

Close Date: 2030-01-01

Grant: Open

Precision medicine Adaptive Network platform Trial in Hypoxemic acutE respiratory failuRe (PANTHER). (Co-Investigator)

Open Date: 2025-01-01

Close Date: 2030-01-01

Grant: Open

Activating at-risk Pregnant persons through step tracking and weekly targets to reduce adverse Outcomes and Cardiometabolic Consequences (APOCC). (Co-Investigator)

Open Date: 2025-01-01

Close Date: 2030-01-01

Articles (21)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2022

Collaborators (32)

Jonathan Sterne

Academic , HDR UK Chief Scientist

University of Bristol

UNITED KINGDOM

Patrick R Lawler

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (21)

Timing, Translation, and Preparedness

Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19

Patterns and Outcomes of Completeness of Revascularization in Patients With Diabetes and Non–ST-Segment–Elevation Myocardial Infarction in Ontario, Canada

Evaluating possible treatment effect heterogeneity in a randomized trial of milrinone versus dobutamine in cardiogenic shock

Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)

Impact of remote biometric sensing on readmission risk and mortality after hospital discharge: Insights from a systematic review and meta‐analysis

Designing Future Cardiac Arrest Trials to Accommodate Heterogeneous Treatment Effects

Peripheral blood neutrophil-to-lymphocyte ratio and long-term outcomes among patients surviving cardiogenic shock

It’s about time: The association between abacavir and cardiovascular disease

Temporary mechanical circulatory support in fulminant myocarditis: can global collaborations bridge the gap?

The evolving role of heparin in sepsis: therapeutic potential in the age of immunothrombosis

Leukocyte Ratios Associate With Vasodilatory Hemodynamics in Cardiac Intensive Care Shock

Pre-discharge neutrophil:lymphocyte ratio and lymphopenia are associated with post-hospital long-term outcomes among survivors of critical illness

Anticoagulation Among Patients Hospitalized for COVID-19: A Systematic Review and Prospective Meta-analysis

Heart failure decompensation with cardiogenic shock exhibits distinct sequential inflammatory profiles

Early Evolution of SCAI Shock Stage and In-Hospital Mortality in the Cardiovascular Intensive Care Unit Population: From the Critical Care Cardiology Trials Network (CCCTN).

Differences in Care and Outcomes in Cardiogenic Shock in Cardiac Intensive Care Units in the United States and Canada: CCCTN Registry Insights

Cardiac Critical Care in 2025 and in 2035

A New Generation of Clinical Endpoints for Critical Care Trials

Dynamic Changes in Right Ventricular Function But Not Left Ventricular Function Are Predictive of Outcomes in Critically-ill Patients With Sepsis

Emerging biomarkers for risk stratification in cardiogenic shock: steps closer to precision?

Collaborators (32)

Jonathan Sterne

Daniel McAuley

Truls Ostbye

Alistair Nichol

Gabriele Lileikyte

Thomas Hills

Alastair Proudfoot

Stephen E. Fremes

Srinivas Murthy

Heather Ross

Erica EM Moodie

Francesca Spiga

Lise Estcourt

Charlotte A. Bradbury

Aidan Burrell

Tobias Tritschler

Lana Wahid

Sylvain A Lother

James Totterdell

Peter Godolphin

Connor O'Brien

Christopher B Granger

Anthony Gramolini

Bala Venkatesh

Yoshiaki Yamagishi

Grégoire Le Gal

Alisa Higgins

Ramon Lecumberri

Peter Austin

Shailesh Bihari

Michael Goldfarb

Darshan H Brahmbhatt

Make your next move.